Tempus AI, Inc. (NASDAQ:TEM) Major Shareholder Bradley A. Keywell Sells 170,720 Shares

Tempus AI, Inc. (NASDAQ:TEM) major shareholder Bradley A. Keywell sold 170,720 shares of Tempus AI stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $35.45, for a total value of $6,052,024.00. Following the transaction, the insider now owns 15,993,729 shares of the company’s stock, valued at $566,977,693.05. This represents a 1.06 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Tempus AI Trading Up 1.2 %

TEM opened at $35.15 on Friday. Tempus AI, Inc. has a 1 year low of $22.89 and a 1 year high of $79.49. The firm has a 50 day moving average price of $46.03 and a 200 day moving average price of $47.18. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on TEM. Needham & Company LLC reissued a “buy” rating and issued a $56.00 target price on shares of Tempus AI in a research note on Tuesday, January 14th. Piper Sandler reiterated a “neutral” rating and issued a $70.00 price target (up from $40.00) on shares of Tempus AI in a report on Tuesday, November 12th. Stifel Nicolaus lowered Tempus AI from a “buy” rating to a “hold” rating and increased their price target for the stock from $45.00 to $65.00 in a research note on Monday, November 11th. Wolfe Research initiated coverage on Tempus AI in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective for the company. Finally, Loop Capital lowered their price target on Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a report on Tuesday, January 14th. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $56.36.

Institutional Investors Weigh In On Tempus AI

Several large investors have recently made changes to their positions in the business. Kovitz Investment Group Partners LLC purchased a new stake in Tempus AI during the 3rd quarter worth $1,367,000. Sumitomo Mitsui Trust Group Inc. lifted its stake in shares of Tempus AI by 1,591.2% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company’s stock worth $68,922,000 after purchasing an additional 1,145,698 shares in the last quarter. Captrust Financial Advisors purchased a new stake in shares of Tempus AI in the third quarter worth about $2,726,000. Sigma Planning Corp acquired a new stake in shares of Tempus AI in the third quarter valued at about $1,323,000. Finally, Dakota Wealth Management acquired a new stake in shares of Tempus AI in the third quarter valued at about $1,185,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.